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Abstract Several population studies relate exposure to high
levels of arsenic with an increased incidence of ischemic heart
disease and cardiovascular mortality. An association has been
shown between exposure to high levels of arsenic and cardio-
vascular risk factors such as hypertension and diabetes
mellitus, and vascular damage such as subclinical carotid
atherosclerosis. The mechanisms underlying these phenome-
na are currently being studied and appear to indicate an
alteration of vascular function. However, the effects of low
levels of exposure to arsenic and their potential detrimental
cardiovascular effect are less explored. The article provides an
overview of the pathophysiologic mechanisms linking low-
level arsenic exposure to the occurrence of cardiovascular
disease and its complications, and some potential preventive
strategies to implement.
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Arsenic (As) is a natural element of the earth's crust whose
toxicity has been known for centuries. Adverse effects depend
on dose, duration, and frequency of exposure, and can range
from neurological and respiratory damage to the onset of can-
cers of the skin, lung, and bladder (Brunton and Knollmann
2011; Longo et al. 2012); the International Agency for
Research on Cancer has classified inorganic As as group 1
human carcinogen (WHO-IARC 2012). Occupational exposure
and intentional poisoning are well-known sources of acute
toxicity, whereas lower-level long-standing exposures require
a broad range of expertise for As detection and the study of
environmental fate and mechanisms of human toxicity. The
main cause of chronic intoxication for the general population
is ingestion of drinking water drilled in deposits contaminated
with this metalloid, occurring mainly in developing countries,
but also to a lesser extent in the Western world (Lisabeth et al.
2010; Medrano et al. 2010). The World Health Organization
and most national legislations have set a limit of 10 μg/L of As
in drinking water, corresponding to the reliable detection
threshold using current methods, while some countries
(especially developing countries) still maintain a threshold of
50 μg/L as recommended by WHO before 1993.
The Joint FAO/WHO Expert Committee on Food
Additives (JECFA) set a provisional tolerable intake (PTWI)
for inorganic As at 2.1 μg/Kg/day or 15 μg/Kg/week (JECFA
1989). The European Food Safety Authority Panel on
Contaminants in the Food Chain (EFSA-CONTAM) noted
that after this PTWI was established, new data showed that
inorganic As causes cancer of the lung and urinary tract in
addition to skin, and a range of adverse effects have been
reported at exposures lower than those reviewed by the
JECFA, concluding that the PTWI of 15 μg/Kg was not
appropriate. In 2010, the JECFA withdrew the PTWI
(JECFA 2011). The main adverse effects reported by the
EFSA-CONTAM Panel associated with long-term ingestion
of inorganic As in humans were skin lesions, cancer, devel-
opmental toxicity, neurotoxicity, cardiovascular (CV) disease,
abnormal glucose metabolism, and diabetes. On the other
hand, evidence of CV disease and diabetes in areas with
relatively low levels of inorganic As exposure was evaluated
as inconclusive (EFSA-CONTAM 2009).
High levels of As exposure in drinking water have been
related to increased risk of CV disease. Since this is a major
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cause of death worldwide, and most of the world's population
resides in developing countries where the incidence of CV
disease is rising, even a modest increase in risk due to As in
groundwater might have substantial impact on morbidity and
mortality.
The fate of As in the human body
The metalloid As is a natural environmental contaminant. It is
present in organic and inorganic form, and in different valence
or oxidation states—mainly the trivalent (III) and pentavalent
(V). The most toxicologically potent As compounds are in the
trivalent oxidation state. Organic arsenicals in the pentavalent
oxidation state—such as those used as pesticides, even to-
day—are much less toxic than inorganic ones because unlike
inorganic As they are not readily taken up by cells, and
undergo limited metabolism (Cohen et al. 2006; Hughes
et al. 2011); concern regarding these compounds is due to
their progressive breakdown to inorganic As in the environ-
ment. As is ubiquitous; diet is the main source of total As for
humans, but the organic compounds normally present in food,
especially in fish and seafood, are considered nontoxic or of
low toxicity. Populations living in coastal areas have on average
higher urinary excretion of As than those living inland, without
this in itself turning out in toxicity (Delgado-Andrade et al.
2003; EFSA-CONTAM 2009; JECFA 2011; WHO-IARC
2012). Total urinary As is an unreliable marker of exposure to
inorganic As, the most toxic form, so studies often adjust this
measurement for seafood consumption (Navas-Acien et al.
2008; Kim and Lee 2011; Moon et al. 2012). Soil, air, and
absorption through the skin are a minor source of As for the
general population, but may be important in professional
exposure.
Conversely, As found in water is almost entirely inorganic,
and drinking water accounts for most exposure to this form. In
water, As is not in its elemental form, which is insoluble, but as
arsenate (pentavalent) in surface water, while arsenite (trivalent)
is more prevalent in deep anoxic wells (Flora 2011;WHO-IARC
2012). Metabolization in the human body is not completely
understood, but the main step is methylation, primarily in the
liver, with or without the involvement of glutathione (GSH)
(Watanabe and Hirano 2012); most excretion in the urine is in
the form of dimethyl, a smaller part as methyl, while about a
quarter is excreted as inorganic (Vahter 2000). While methyla-
tion is a detoxification process (Huang et al. 2009), some of the
intermediate metabolites, particularly those with trivalent As,
couldmediate some of the toxic and carcinogenetic effects of As.
The precise mode of action of As toxicity is even less well-
known. Several modes of action, possibly interrelated, have
been proposed as follows: interaction with sulfur and binding
to sulfhydryl groups on proteins and enzymes; substitution of
arsenate for phosphate, since As and phosphorus both belong
to group 15 of the periodic table and share physiochemical
properties, cutting off ATP formation in particular; substitu-
tion for zinc in zinc fingers; genotoxic action, potentiating the
mutagen action of other compounds but also inhibiting DNA
enzymatic repair and altering DNA methylation; and alter-
ation of cellular signal transduction (Hughes et al. 2011; Flora
2011). The formation of reactive oxygen species (ROS), also
occurring at concentrations that are not directly cytotoxic
(Barchowsky et al. 1996), could be the pathogenic mechanism
for the observed CVeffects.
As and CV disease
Several epidemiological studies in different countries have
found a relationship between exposure to high levels of
As—as high as >50 μg/L in drinking water, but the limits
used to define “high,” “moderate,” or “low” referring to
nonprofessional exposure vary widely—and CV disease.
The relationship is particularly evident for peripheral arterial
disease (“blackfoot disease” is a form of PAD endemic to
areas of Taiwan with extremely high levels of As in drinking
water (Tseng 1977)) and coronary heart disease, while the
association with stroke is less strong and of borderline signif-
icance (Lisabeth et al. 2010; Moon et al. 2012). The studies
globally show a temporal sequence between time of exposure
and onset of disease, have yielded consistent results in differ-
ent countries and populations, show a dose–response relation,
and show decreased incidence of disease where reduced ex-
posure has been implemented (Chang et al. 2004; Yuan et al.
2007). The association between As and CV disease is at least
partly independent of traditional risk factors. Prospective stud-
ies do confirm the association (Chen et al. 2011b) and various
biological mechanisms for CV toxicity have been investigat-
ed; all this is enough to define a causal relationship, i.e., a high
level of As exposure is an established risk factor for CV
disease (Saposnik 2010; Moon et al. 2012).
Less is known about the CVeffects of exposure to lower As
levels, closer to the WHO threshold, which interests a much
larger population worldwide. Results are conflicting; at these
levels, the magnitude of the effect is expected to be smaller,
and methodological limitations—mainly the difficulty of
assessing actual and cumulative individual exposure, but also
the distinction between organic and inorganic As, and out-
come measures with the potential confounders—may have
played a role in the non-significance of most statistical asso-
ciations performed so far.
As in the CV continuum
As has been associated in a dose-dependent manner with high
blood pressure (Wang et al. 2011; Abhyankar et al. 2012),
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even at low levels of exposure (Zhang et al. 2012a), and with
renal dysfunction (Chen et al. 2011a) and proteinuria (Chen
et al. 2011c). The association with diabetes has been limited to
sufficient evidence for high levels (Maull et al. 2012), while
some recent data (Jovanovic et al. 2012) conducted with more
precise exposure measurements assessing the relation with
glucose metabolism (Del Razo et al. 2011) suggest an associ-
ation even at lower levels (Huang et al. 2011; Maull et al.
2012). The pathophysiological mechanism could be a direct
toxic effect on beta-cells, interaction with cellular signaling, or
enzyme inhibition in beta-cells or in peripheral tissues (Huang
et al. 2011). Consistent with the association with risk factors
and CV disease, an association has also been found between
As exposure and atherosclerosis (Wang et al. 2002; Wang
et al. 2010; Hsieh et al. 2011), and confirmed in experimental
animal studies (Bunderson et al. 2004; Srivastava et al. 2009;
Lemaire et al. 2011).
Endothelial dysfunction: the link between As and CV
disease?
Oxidative stress is an established and widely studied mecha-
nism of As toxicity. ROS are formed both in vivo and in vitro
in the presence of As. They include superoxide anion, hy-
droxyl radical, hydrogen peroxide, reactive nitrogen species,
and As-centered and As peroxyl radicals (Bao and Shi 2010b;
Hughes et al. 2011; Flora 2011). The mechanisms of ROS
formation by As are not completely clear; they may be pro-
duced during oxidation of arsenite (III) to arsenate (V) during
metabolization, by stimulation of the enzymes NADH or
NADPH oxidase (Smith et al. 2001), and NOX (States et al.
2009), or by mobilization of free iron from ferritin (Shi et al.
2004; Flora 2011; Jomova et al. 2011).
Nitric oxide (NO) is one of the main mediators released
from the endothelium. It has vasodilatory and anti-
inflammatory properties, and inhibits platelet adhesion and
aggregation, as well as smooth muscle cell proliferation and
migration. ROS inactivate NO and reduce its bioavailability in
the vascular endothelium. In addition to the direct action of
ROS on NO, As inhibits endothelial NO synthetases (eNOS)
(Fig. 1) (Lee et al. 2003; Tsou et al. 2005; Li et al. 2007),
depletes GSH—one of the main antioxidant ROS scaven-
gers—and inhibits redox enzymes (catalase, glutathione per-
oxidase and reductase, thioredoxin reductase, and superoxide
dysmutase). The disruption of antioxidant defense mecha-
nisms and the blocking of new NO formation further decrease
NO bioavailability and increase endothelial dysfunction (Pi
et al. 2000). It is notable that acute exposure or low doses do
actually induce redox enzymes, indirectly confirming their
role in As detoxification (Shi et al. 2004; Flora 2011).
Consistently with the oxidative stress frame, several antioxi-
dants have shown, in vivo or in vitro, a protective effect
against As-induced toxicity. These include N-acetylcysteine
(Bao and Shi 2010a), alpha-lipoic acid, vitamin C and E,
taurine, quercetin (Ghosh et al. 2011), some plant extracts
including garlic (Balakumar and Kaur 2009; Biswas et al.
2010; Flora 2011), and resveratrol (Zhao et al. 2008b; Zhang
et al. 2012b).
When NO concentrations are reduced, the endothelial sur-
face becomes more prone to atherosclerosis, cell adhesion, and
thrombosis, a condition known as endothelial dysfunction,
common to all major CV risk factors (aging, hypertension,
diabetes, dyslipidemia, etc.) (Deanfield et al. 2007). One of
the mechanisms by which As induces endothelial dysfunction
is by exaggerating calcium influx in cells (Suriyo et al. 2012).
Exposure to As augments endothelial permeability through
increased VEGF expression (Bao and Shi 2010a) and reduces
proteoglycan synthesis in endothelial cells (Fujiwara et al.
2005); individuals drinking water contaminated with As show
dose-dependent expression of plasma levels of cell adhesion
molecules, i.e., a pro-atherosclerotic endothelium (Chen et al.
2007).While it is known that As enhances oxidative stress, and
that oxidative stress produces endothelial dysfunction, the
direct link between exposure to As and endothelial dysfunction
in humans has not been investigated extensively. There are no
published studies on As and in vivo endothelial function, either
in small vessels (venous plethysmography) (Joannides et al.
2006) or conduit vessels (flow-mediated dilation) (Deanfield
et al. 2007).
Other mechanisms of CV damage
Endothelial dysfunction characterizes arterial hypertension,
and pharmacological blockade of eNOS by L-NMMA raises
blood pressure (Owlya et al. 1997), so diminished NO avail-
ability is a plausible mechanism to link As with hypertension
(Hsueh et al. 2005). Moreover, As decreases in vitro vascular
relaxation capability, both endothelium-dependent and
endothelium-independent, directly acting on the smooth mus-
cle cells (Lee et al. 2003), while it potentiates response to
vasoconstrictors through myosin light chain phosphorylation
and Ca++ sensitization/inflow (Lee et al. 2005; Li et al. 2010;
Lim et al. 2011). Interaction with arachidonic acid biotrans-
formation, influencing vasoconstriction and relaxation, may
be another mechanism (Bunderson et al. 2004). Renal damage
may be involved in raising blood pressure (Chen et al. 2011c;
Hsueh et al. 2009), but the causal relationship with this asso-
ciation remains to be clarified.
As exposure in a wide range of levels is consistently
associated with QT prolongation—a risk factor for arrhythmia
and sudden cardiac death—torsade de pointes (Ficker et al.
2004; Mumford et al. 2007; Mordukhovich et al. 2009; Wang
et al. 2009), and increased QT dispersion (Wang et al. 2010).
As may act on QT by increasing cardiac calcium currents
246 Environ Sci Pollut Res (2014) 21:244–251
(Ficker et al. 2004), but no protective effect of calcium antag-
onists has been found (Mordukhovich et al. 2009), and there
are conflicting data on verapamil enhancing or reducing As
cardiotoxicity (Zhao et al. 2008a; Luong and Rabkin 2009).
Through the abovementioned mechanisms, As also exerts
its direct cytotoxic effects on cardiomyocytes, inducing apo-
ptosis or necrosis (Zhao et al. 2008a; Luong and Rabkin
2009); moreover, the myocardium appears to be a sensitive
target tissue for As (Roman et al. 2011). However, population
data are scarce, while cardiotoxicity of As2O3 as a chemother-
apeutic drug is well known, and is more marked in Afro-
Americans, probably due to genetic susceptibility (Patel
et al. 2006). Specific effects of As on the heart could explain
the disproportionate increase in CVevents compared to stroke
despite the known effect on blood pressure (Zierold et al.
2004; Lisabeth et al. 2010). Although there appear to be no
studies regarding a relationship between heart failure or car-
diomyopathy and As, there are hints of a synergistic toxic
effect of As and alcohol on the heart (Navas-Acien et al. 2006;
Bao and Shi 2010b).
Polymorphisms in the genes of enzymes involved in As
metabolism, especially As methyltransferase, and in redox
enzymes can modulate As toxicity and its CV effects (Vahter
2000; Hsueh et al. 2005; States et al. 2009; Hsieh et al. 2011;
Hughes et al. 2011).
Reduced synthesis of extracellular matrix and damage to
vascular smooth muscle cells are other mechanisms that could
promote atherosclerotic plaque formation and instability
(Hays et al. 2008; Li et al. 2010), while oxidation of lipids
would make them more prone to be internalized in the vessel
wall (Srivastava et al. 2009). As appears to enhance platelet
aggregation (Lee et al. 2002), possibly by exposing
phosphatidylserine (Bae et al. 2009), though studies are
conflicting (Lin et al. 2010), and reduces endothelial fibrino-
lytic activity by reducing t-PA and increasing PAI-1 level and
activity (Jiang et al. 2002), and reduces synthesis of
Fig. 1 Arsenic and endothelial
dysfunction.ATG angiotensinogen,
AT angiotensin, ACE angiotensin
converting enzyme, ET endothelin,
COX cyclooxygenase, PG
prostaglandin, TX tromboxane,
NADPH nicotinamide dinucleotide
phosphate, eNOS endothelial
nitric oxide synthase, NO nitric
oxide, cGMP cyclic guanosine
monophosphate, and EDHF
endothelium-derived
hyperpolarizing factors
Fig. 2 Arsenic and mechanisms
of CV damage. SMC smooth
muscle cells, GSH glutathione,
t-PA tissue plasminogen
activator, and PAI-1
plasminogen activator
inhibitor type 1
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proteoglycans such as heparan sulfate (Fujiwara et al. 2005).
The activity of As on coagulation and platelets could aggra-
vate thrombosis when the atherosclerotic plaque ruptures
(Fig. 2).
CV toxicity of As: diagnosis and therapy
CV toxicity due to As exposure can be suspected based on
personal history. Professional exposure is a concern for people
working in mines, the wood industry, coal-fired power plants,
ore smelting, battery assembly, and electronics. Intentional
poisoning was considered a “perfect crime” in the past, since
As is odorless and tasteless and symptoms of acute intoxica-
tion are quite aspecific, but its use has become rare since As is
now detectable in fluids and tissues (Hughes et al. 2011).
Contamination of drinking water is usually well-known in
particular areas. The patient should be carefully questioned
and examined for other As-associated diseases, such as skin
lesions and cancers. Hints from clinical history and examina-
tionmust be confirmed by evidence of As levels in body fluids
and tissues indicative of exposure (Das and Sengupta 2008;
Marchiset-Ferlay et al. 2012). Since As is metabolized from
the blood within a period of hours, blood As levels—normally
<1 μg/l—are not a good indicator of long-term exposure, and
they are only partially correlated with As in drinking water.
The majority of absorbed As is excreted in the urine, normally
within 1–2 days, so that urinary As is considered a reliable
marker of recent exposure (Jomova et al. 2011). However, as
previously mentioned, not all forms of As are (equally) toxic,
so total urinary As should be considered only a screening test,
or suitable for population studies or continuous professional
exposure. Distinguishing organic from inorganic forms, and
between oxidation states, requires more complex methods
such as chromatographic techniques or spectrometry, and
special care in managing the sample—adjusting for seafood
consumption, the major source of organic As—is neither
reliable nor plausible on a routine basis at the individual level.
Studying As in toenails and hair, where trivalent As binds with
sulfhydryl groups in keratin, provides information on a more
long-term exposure. As species are more stable in these sam-
ples, and most of the As is inorganic; on the other hand, the
correlation between toenail As and exposure to inorganic As is
poor (Hinwood et al. 2003; Slotnick and Nriagu 2006).
Variable growth rate of skin appendages could be another
confounding factor (Das and Sengupta 2008; Marchiset-
Ferlay et al. 2012).
There are no guidelines or consensus statements that tell
the clinical cardiologist when to screen for As exposure, but
aside from confirmation of exposure suspected on the basis of
history or environment, a reasonable approach might be to
search for As in patients when arrhythmias or CVevents occur
without obvious cause or in absence of traditional risk factors.
Patients diagnosed with As poisoning should be promptly
removed from sources of the metalloid and provided with
supportive measures and specific care for the diseases devel-
oped, along with treatment of symptoms and correction of
nutritional deficits (States et al. 2009) and electrolyte imbal-
ance, which increases the risk for arrhythmias. The most
effective specific treatment for arsenicosis is chelation therapy
(Brunton and Knollmann 2011; Longo et al. 2012); however,
it is limited to life-threatening conditions due to its potentially
severe side effects. Most of the effects of antioxidants have
been tested either in vitro, on animals, or (in humans) on soft
endpoints (Biswas et al. 2010), but there is some indication of
their usefulness as adjunctive therapy during chelation, espe-
cially for N-acetylcysteine (Flora et al. 2007).
Conclusions
Several studies suggest CV effects of As exposure at low-to-
moderate levels. These effects may translate into a higher CV
mortality; however, studies on mortality from CV disease
have been inconsistent. Although the mechanisms through
which As can cause atherosclerotic lesions and their compli-
cations have been explored, individual risks from environ-
mental pollution remain to be established. Many factors make
the assessment of such a relationship quite difficult, such as
the means of measurement, confounding factors from conven-
tional risk factors for CV disease, and the variability of thresh-
old allowed by individual countries for As pollution. It is time
tomove from population to individual risk assessment in order
to profile the real impact of As exposure at low doses through
imaging biomarkers of atherosclerosis. More prospective
studies designed to assess doses (thresholds) and risks and
individual susceptibility through genetic testing are needed to
explore the relationship between As exposure and the occur-
rence of CV disease and its complications.
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